Form 4: J&J CFO Exercises Options, Sells Shares

Johnson & Johnson's Executive VP and CFO, Joseph J. Wolk, exercised stock options and subsequently sold the acquired shares for personal financial planning.

Summary

• Joseph J. Wolk, Executive VP and CFO of Johnson & Johnson (JNJ), reported transactions on August 15, 2025.
• Exercised 16,820 employee stock options at an exercise price of $101.87 per share.
• Immediately sold 16,820 shares of Common Stock at a weighted average price of $176.9067 per share.
• The options were granted with an exercise price of $101.87 and became exercisable on February 9, 2019, expiring on February 8, 2026.
• Following these transactions, Wolk directly holds 14,000 shares of Common Stock.
• Indirect holdings include 68,835 shares in a spousal lifetime access trust (SLAT) and 2,145 shares in a 401k plan, which includes shares from dividend reinvestment as of July 31, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (exercise of options and sale of shares) which is a common occurrence for executives realizing compensation. It does not inherently indicate positive or negative operational performance or strategic shifts for the company, thus a neutral sentiment.

Positives

• The exercise of options indicates the realization of value from long-term incentive compensation for the executive.
• The options were significantly "in the money," with an exercise price of $101.87 compared to a sale price of $176.9067, indicating a substantial gain for the executive.

Negatives

• The sale of shares by a key executive, even if tied to option exercise, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake.

Risks

• No specific risks to the company's operations or financial health are disclosed in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as its purpose is solely to report insider transactions.

Industry Context

This filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares by a senior executive. Such transactions are common across all industries as a mechanism for executives to realize value from their compensation packages and manage personal finances. It does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical or consumer health sectors.

Comparison to Industry Standards

• The structure of executive compensation, including stock options, is standard practice for large, publicly traded companies like Johnson & Johnson, aligning executive incentives with shareholder value.
• The exercise-and-sell transaction type is a common method for executives to monetize vested options while managing tax implications and personal liquidity, consistent with practices observed at peer companies such as Pfizer, Merck, or Abbott Laboratories.
• The disclosure of direct and indirect holdings, including through trusts and retirement plans, adheres to SEC reporting requirements for insider ownership, comparable to disclosures from executives at other S&P 500 companies.

Related Party Transactions

• Joseph J. Wolk indirectly holds 68,835 shares of Common Stock in a spousal lifetime access trust (SLAT), where his spouse is the trustee and beneficiary. This is a common structure for executive holdings and is disclosed as an indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if tied to option exercise, could be viewed by some as a slight reduction in management's direct equity alignment, though it's a routine compensation event.
• Employees: No direct impact on employees is indicated by this insider transaction report.
• Customers: No direct impact on customers is indicated by this insider transaction report.
• Suppliers: No direct impact on suppliers is indicated by this insider transaction report.
• Creditors: No direct impact on creditors is indicated by this insider transaction report.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Keywords

Johnson & Johnson, JNJ, Joseph J. Wolk, Insider Trading, SEC Form 4, Stock Options, Executive Compensation, Share Sale, Beneficial Ownership